Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
CNXB– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations –
August 13, 2025Earnings
Read more →